Page 207 - Read Online
P. 207

46.  Buck  E,  Gokhale  PC,  Koujak  S,  Brown  E,  Eyzaguirre  A,   of  apoptosis  in  brain  cancer  cells  by  targeted  codelivery  of
               Tao  N,  Rosenfeld-Franklin  M,  Lerner  L,  Chiu  MI,  Wild  R,   siRNA and anticancer drugs. Mol Pharm 2011;8:1955-61.
               Epstein  D,  Pachter  JA,  Miglarese  MR.  Compensatory  insulin   56.  Kunnath AP, Tiash S, Fatemian T, Morshed M, Mohamed SM,
               receptor  (IR)  activation  on  inhibition  of  insulin-like  growth   Chowdhury  EH.  Intracellular  delivery  of  ERBB2  siRNA  and
               factor-1  receptor  (IGF-1R):  rationale  for  cotargeting  IGF-1R   p53  gene  synergistically  inhibits  the  growth  of  established
               and IR in cancer. Mol Cancer Ther 2010;9:2652-64.  tumour  in  an  immunocompetent  mouse.  J  Cancer  Sci  Ther
            47.  Flanigan  SA,  Pitts  TM,  Eckhardt  SG,  Tentler  JJ,  Tan  AC,   2014;6:99-104.
               Thorburn  A,  Leong  S.  The  insulin-like  growth  factor  I   57.  Yoshizawa  T,  Hattori  Y,  Hakoshima  M,  Koga  K,  Maitani  Y.
               receptor/insulin  receptor  tyrosine  kinase  inhibitor  PQIP   Folate-linked  lipid-based  nanoparticles  for  synthetic  siRNA
               exhibits  enhanced  antitumor  effects  in  combination  with   delivery  in  KB  tumor  xenografts.  Eur J Pharm Biopharm
               chemotherapy  against  colorectal  cancer  models.  Clin Cancer   2008;70:718-25.
               Res 2010;16:5436-46.                           58.  Kunnath   AP,   Kamaruzman   NI,   Chowdhury   EH.
            48.  Chen  YF,  Fu  LW.  Mechanisms  of  acquired  resistance  to   Nanoparticle-facilitated intratumoral delivery of Bcl-2/IGF-1R
               tyrosine kinase inhibitors. Acta Pharm Sin B 2011;1:197-207.  siRNAs  and  p53  Gene  synergistically  inhibits  tumor  growth
            49.  Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G,   in  immunocompetent  mice.  J  Nanomedicine  Nanotechnol
               Schlitt  HJ,  Geissler  EK,  Stoeltzing  O,  Lang  SA.  Targeting   2014;S9:001.
               FGFR/PDGFR/VEGFR  impairs  tumor  growth,  angiogenesis,   59.  Niu  J,  Xu  Z,  Li  XN,  Han  Z.  siRNA-mediated  type  1
               and  metastasis  by  effects  on  tumor  cells,  endothelial  cells,   insulin-like  growth  factor  receptor  silencing  induces
               and  pericytes  in  pancreatic  cancer.  Mol Cancer Ther   chemosensitization  of  a  human  liver  cancer  cell  line  with
               2011;10:2157-67.                                   mutant P53. Cell Biol Int 2007;31:156-64.
            50.  Escudier  B,  Grünwald  V,  Ravaud  A,  Ou  YC,  Castellano  D,   60.  Xie  L,  Kassner  M,  Munoz  RM,  Que  QQ,  Kiefer  J,  Zhao  Y,
               Lin  CC,  Gschwend  JE,  Harzstark  A,  Beall  S,  Pirotta  N,   Mousses  S,  Yin  HH,  Von  Hoff  DD,  Han  H.  Kinome-wide
               Squires  M,  Shi  M,  Angevin  E.  Phase  II  results  of   siRNA  screening  identifi es  molecular  targets  mediating
               Dovitinib  (TKI258)  in  patients  with  metastatic  renal  cell   the  sensitivity  of  pancreatic  cancer  cells  to  Aurora  kinase
               cancer. Clin Cancer Res 2014;20:3012-22.           inhibitors. Biochem Pharmacol 2012;83:452-61.
            51.  André   F,   Bachelot   T,   Campone   M,   Dalenc   F,   61.  Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C,
               Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW,   Mackay  A,  Grigoriadis  A,  Sarrio  D,  Savage  K,  Dexter  T,
               Deudon  S,  Shi  M,  Zhang  Y,  Kay  A,  Porta  DG,  Yovine  A,   Iravani  M,  Fenwick  K,  Weber  B,  Hardisson  D,  Schmitt  FC,
               Baselga  J.  Targeting  FGFR  with  dovitinib  (TKI258):   Palacios  J,  Lakhani  SR,  Ashworth  A.  FGFR1  emerges  as  a
                                                                  potential therapeutic target for lobular breast carcinomas. Clin
               preclinical  and  clinical  data  in  breast  cancer.  Clin Cancer   Cancer Res 2006;12:6652-62.
               Res 2013;19:3693-702.
            52.  Kalota  A,  Shetzline  SE,  Gewirtz  AM.  Progress  in  the   62.  Turner  N,  Pearson  A,  Sharpe  R,  Lambros  M,  Geyer  F,
                                                                  Lopez-Garcia  MA,  Natrajan  R,  Marchio  C,  Iorns  E,
               development  of  nucleic  acid  therapeutics  for  cancer.  Cancer   Mackay  A,  Gillett  C,  Grigoriadis  A,  Tutt  A,  Reis-Filho  JS,
               Biol Ther 2004;3:4-12.                             Ashworth  A.  FGFR1  amplifi cation  drives  endocrine  therapy
              53.  Lu  PY,  Xie  F,  Woodle  MC. In vivo  application  of  RNA   resistance and is a therapeutic target in breast cancer.  Cancer
               interference:  from  functional  genomics  to  therapeutics.  Adv   Res 2010;70:2085-94.
               Genet 2005;54:117-42.                          63.  Niu  J,  Li  XN,  Qian  H,  Han  Z.  siRNA  mediated  the  type  1
            54.  Chowdhury EH. Nuclear targeting of viral and non-viral DNA.   insulin-like  growth  factor  receptor  and  epidermal  growth
               Expert Opin Drug Deliv 2009;6:697-703.             factor  receptor  silencing  induces  chemosensitization  of  liver
              55.  Kim C, Shah BP, Subramaniam P, Lee KB. Synergistic induction   cancer cells. J Cancer Res Clin Oncol 2008;134:503-13.

































            200                                   Journal of Cancer Metastasis and Treatment  ¦  Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦
   202   203   204   205   206   207   208   209   210   211   212